Наукові статті

Permanent URI for this collectionhttps://ir.kmu.edu.ua/handle/123456789/85

Browse

Browsing Наукові статті by Issue Date

Filter results by year or month
Now showing 1 - 20 of 47
  • No Thumbnail Available
    Item
    CARDIOTROPIC INFLUENCE OF SYNTHETIC AND GENETICALLY-ENGINEERED SUPPRESSORS IN RATS WITH EXPERIMENTAL RHEUMATOID ARTHRITIS COMBINED WITH ARTERIAL HYPERTENSION
    (Світ медицини та біології, 2020) Seredynska N.M.; Korniyenko V.I.; Marchenko-Tolsta K.S.; Bobrytska O.M.; Ladohubets O.V.; Duchenko K.A.
    Significant progress in rheumatoid arthritis pharmacotherapy is associated with the implementation of synthetic–derived immunosuppressors and genetically engineered (biological) drugs) into clinical practice. Arterial hypertension, like rheumatoid arthritis, is accompanied by producing a large amount of inflammatory cytokines, namely TNF–ά. The purpose of the work was to study the cardiotropic effects of leflunomide and etanercept against the background of experimental rheumatoid arthritis associated with arterial hypertension in rats. Experiments on mature adult, non-linear white rats found that leflunomide and etanercept did not affect the degree of hypertension against the background of adjuvant arthritis, but manifested an antihypertensive effect when used in adjuvant arthritis combined with arterial hypertension. Leflunomide leads to an increase in heart rate by 5–10.4% at different terms of observation, both against the background of adjuvant arthritis only and under the combined pathology conditions. Etanercept, when used against adjuvant arthritis, causes bradycardia but prevents the development of tachycardia, which is detected in untreated animals with a comorbid condition during manifestation and attenuation of the inflammatory process. The study findings may be relevant for development of new approaches to the treatment of rheumatic and cardiac pathology.
  • No Thumbnail Available
    Item
    КАРДІОТРОПНА ДІЯ ЛЕФЛУНОМІДУ ЗА УМОВ ВЗАЄМОДІЇ З АМЛОДИПІНОМ НА ТЛІ ЕКСПЕРИМЕНТАЛЬНОГО РЕВМАТОЇДНОГО АРТРИТУ
    (Національний фармацевтичний університет, 2020-03-13) Серединська Н.М.; Марченко О.М.; Хоменко В.С.; Марченко-Толста К.С.; Бершова Т.А.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    NOVEL THERAPEUTIC AGENTS IN CONSTIPATION
    (Sole proprietorship -Gulyaeva V.М., 2020-05-18) Парчамі Газае Сепіде
    Gastrointestinal (GI) disease is prevalent and considered for a large number of death worldwide. Recently many new drugs are developed to treat one of the common GI disorders, functional constipation. Linaclotide is a secretagogue agent, an agonist of the guanylate cyclase-C receptor. It is a safe and effective drug with diarrhea as the main side effect (Bassotti, 2018). Prucalopride is a prokinetic agent newly approved in Canada and by the United States Food and Drug Administration (US FDA) for treating chronic idiopathic constipation. Prucalopriderepresents its effect by stimulating 5-hydroxytryptamine receptor 4 (5-HT4), increasing GI motility in large bowl, accelerating gastric emptying and improving small bowel movement. Efficacy and safety of this drug is documented by different clinical trials. Prucalopride has also shown efficacy in pediatric constipation(Voelker, 2019; Tameez, 2019). Lubiprostone is another approved drug by FDA. It affects luminal GI epitheliumchloride channels, exhibits influx of chloride ions and water into the lumen, increasing intestinal motility represents anti constipation effect. Several randomized controlled trials proved the efficacy of drug in short term treatment although different side effects such as nausea, abdominal pain and bloating, discomfort and headache were also reported. According to researches lubiprostone is more effective but costlier in comparison with Prucalopride. The higher cost of lubiprostone should be considered as a main limiting factor for using this drug (Hayat, 2019). Mizagliflozin is known as a new class of drug for treatment of chronic constipation and irritable bowel syndrome with constipation. Drug is an inhibitor of the sodium-glucose co-transporter 1(SGLT1) in the small intestine epithelium. Although according to different clinical trials Mizagliflozin increases the number of spontaneous bowel movements (SBMs) per week and exhibits dose-dependent efficacy and good tolerability, it needs more long term clinical trials to show the effect of drug in quality of life(Fukudo, 2018). Also, the effect of probiotics as a treatment for constipation is under investigation. probiotics (Bifidobacterium longum) significantly improves constipation in elderly individuals (Martínez-Martínez, 2017). Interestingly, researchers propose new insight into probiotics establishment in human gut mucosal. They suggest that human stool microbiome is more similar to lower GI taxa than upper GI. Moreover, probiotics represent temporary and person feature-dependent effect on mucosal structure and transcriptome (Zmora, 2018). Development of new therapeutic in chronic constipation provides opportunity for physicians to treat patients who experience significant constipation symptoms.
  • No Thumbnail Available
    Item
    MODERN APPROACHES TO DEVELOPMENT OF NANO-SYSTEMS FOR DRUG DELIVERY/ СУЧАСНІ ПІДХОДИ ДО РОЗРОБКИ НАНОСИСТЕМ ДОСТАВКИ ЛІКІВ
    (RS Global Sp. z OO, 2020-06-30) Брубейкер І. О.; Білан О. А; Марченко-Толста К. С.
    The review investigates the latest developments in the field of application of nanotechnologies in the transportation of therapeutic agents, features and the advantages of using nanoscale drug delivery systems for the treatment of diseases, as well as further prospects of using this field in medicine. Modern drug delivery systems are characterized by targetorientation, rapid response to the environment and the use of biocompatible and biodegradable nanomaterials which allow for the development of the next generation of more effective drugs. Interdisciplinary research in this fast-growing field provides opportunities to design and develop multifunctional devices that can accurately target and successfully administer the release and distribution of active ingredients in the body.
  • No Thumbnail Available
    Item
    ВИКОРИСТАННЯ ПОРТФОЛІО В РАМКАХ ВИКЛАДАННЯ ДИСЦИПЛІНИ «УПРАВЛІННЯ КАР’ЄРОЮ»
    (Gulyaeva V.М., 2020-07-24) Білан Ольга Анатоліївна; Новикова Лариса Георгіївна; Марченко-Толста Катерина Сергіївна
    У статті досліджується досвід провідних учбових закладів світу у використанні портфоліо в процесі підготовки студентів-фармацевтів до успішного працевлаштування, кар’єрного зростання та подальшого професійного розвитку, а також узагальнюється досвід авторів з використання портфоліо в рамках викладання дисципліни «Управління кар’єрою» на фармацевтичному факультеті ПВНЗ «Київський медичний університет»
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    USE OF BIOSIMILARS IN MEDICINE
    (Sole proprietorship -Gulyaeva V.М, 2020-07-26) Sepideh Parchami Ghazaee
    Biosimilars are worldwide approved biologic products (originator), complex and large molecules that are highly similar to the reference drug according to structure, function, clinical and quality characteristics, representing no clinically noteworthy differences in safety, purity, or potency and immunogenicity in comparison to biologic drugs. While high cost of healthcare system limits the access of patient population to treatment, biosimilars considered as important healthcare treatment options, reducing the costs for patients and for insurance companies. Development and regulatory approval of biosimilars need specific guide-line developed by The European Medicines Agency, United States Food and Drug Administration and World Health Organization. (Ahmed, 2016; Pittman, 2019). At present there are some approved biosimilars in oncology and treatment of autoimmune diseases. Biologics (monoclonal antibodies [mAbs] and hematopoietic agents) are recommended in oncology guidelines and supportive oncology care (reducing common adverse effects following chemotherapy), enhancing clinical, health-related quality of life. Biologics such as Epoetin alfa, darbepoetin, Filgrastim and its analog and pegfilgrastim that are produced using recombinant DNA technology are included as agents that provide restoring hematological response. Also, it is worthy of note that biosimilars are not only widely used in cancer treatment and supportive care in Europe and USA, but in the Middle east and Asia because of cost saving and the same safety and efficacy. Since regulatory framework for biosimilars introduced in Europe earlier than USA, higher number of these agents are approved by European countries according to nonclinical and pharmaceutical evidences. (Patel, 2018).It is well-known that biologics (biosimilars) have considerable effect on the clinical management of inflammatory conditions like rheumatoid arthritis, inflammatory bowel diseases, and immune-mediated inflammatory conditions such as psoriasis, and psoriatic arthritis. biosimilars for infliximab, then etanercept and finally adalimumab are approved by European countries for treatment of immune-mediated inflammatory diseases (Baumgart, 2019). There are different factors affecting improvement of patient access to biosimilars. Low cost of biosimilars relative to reference products is an important advantage can improve patient access. Knowledge of physicians, patient understanding about variety of benefits of biosismilars and supporting patients by marketing communications and public relations may encourage the use of these agents. Efficacy, quality and safety of biosimilars may ensure patients make treatment decision (Kim, 2020).
  • No Thumbnail Available
    Item
    ВИКОРИСТАННЯ ПОРТФОЛІО В РАМКАХ ВИКЛАДАННЯ ДИСЦИПЛІНИ «УПРАВЛІННЯ КАР’ЄРОЮ»
    (Sole proprietorship -Gulyaeva V.М., 2020-07-26) Білан Ольга; Новикова Лариса; Марченко-Толста Катерина
    У статті досліджується досвід провідних учбових закладів світу у використанні портфоліо в процесі підготовки студентів-фармацевтів до успішного працевлаштування, кар’єрного зростання та подальшого професійного розвитку, а також узагальнюється досвід авторів з використання портфоліо в рамках викладання дисципліни «Управління кар’єрою» на фармацевтичному факультеті ПВНЗ «Київський медичний університет»
  • No Thumbnail Available
    Item
    NOVEL THERAPEUTIC AGENTS IN SKIN DISEASES
    (2020-09-18) Parchami Ghazaee Sepideh
    Use of monoclonal antibodies (mAbs) in feild of diagnostic and therapy is evident. They are developed to treat cancer, immune and infectious diseases (Rajewsky, 2019). Biologic agents are essential alternative for treating different skin diseases. Etanercept, infliximab and adalimumab are used to treat moderate-to-severe plaque psoriasis. These mAbs inhibit TNF (Tumor necrosis factor)-α and approved by FDA (US Food and Drug Administration). Also, Secukinumab and ixekizumab are anti IL-23/IL-17A receptors that received FDA approval and show high efficacy to treat plaque psoriasis. It is worthy of note that secukinumab received FDA approval for arthritic psoriasis. The biosimilars for the 3 anti–TNF-a etanercept, adalimumab and infliximab have been officiallyFDA approved since 2016 and represent a potential cost savings ( Veilleux; Shear, 2017).Dupilumab is a IL-4 receptor -α antibody that inhibits IL-4 and IL-13 signaling targeting atopic dermatitis (AD). This agent showed valid results in phase 3 trial and still under investigation by Eroupian union and Japan according to safety and efficacy. There are some other biologic agents as like Mepolizumab, Tralokinumab, lebrikizumab, Nemolizumab, Ustekinumab and Apremilast in a phase II study in the therapy of AD. (Veilleux; Shear, 2017, Del Rosso (2019).Dacarbazine and IL-2 are two new FDA approved medications for advanced melanoma, although survival rate was not improved by these drugs. Ipilimumab is a fully human mAb (IgG1) that restricts T cell activation by inhibiting cytotoxic T lymphocyte–associated antigen 4 (CTLA-4); drug showed these effects in phase 3 trial and enhanced survival in melanoma. Dabrafenib and and trametinib are inhibitors of the mitogen-activated protein kinase pathway and FDA approved in melanoma. For some of these drugs response rate is high although, duration of maintenance of effect is low. Ipilimumab represent only 10.9% response rate is but with a quite high maintained response of 60% at 2 years. Pembrolizumab and nivolumab, programmed cell death-1 (PD-1) inhibitor antibodies with 30% to 40% and durable response rate. Demonstrating some adverse effects in patients giving immunotyherapy should be considered. Using lower doses with assuring response rate may minimize side effects. Pidilizumab and atezolizumab are some other PD-1 targeting agents under different phases of investigations. Biologic agents may be possible effective approaches for patients with hidradenitis suppurativa (HS).
  • No Thumbnail Available
    Item
    PRE-IRRADIATION OF A SOLVENT – A WAY TO RESPECT THE THERAPEUTIC EFFCACY OF SOME WATER- SOLUBLE DRUGS
    (Державне підприємство «Редакція інформаційного бюлетеня «Офіційний вісник Президента України», 2020-09-23) M.A. Zabolotnyy; G.I. Dovbeshko; V.E. Orel; G.I. Solyanik; L.N. Kirkilevskaya
    The work is devoted to the study of the processes that determine the possibilities of the method of increasing the effectiveness of the antitumor action of already known antitumor drugs without the use of foreign nano dipurities using high-energy electron irradiation. The electron energy was 2 MeV. The method is based on the use of the original technique, which uses irradiation of the solvent (water or saline) before the introduction of a drug (doxorubicin). Conformational changes in doxorubicin molecules in irradiated saline were analysed by changes in their vibrational spectra, which were recorded using an IR-Fourier spectrometer. Quantum chemical calculations were performed using the Gaussian program, the method of density functional (B3LYP). The geometry of the doxorubicin molecule was optimized and its oscillation spectrum was calculated. To study the pharmacological activity of the antitumor drug doxorubicin used Lewis lung carcinoma. Cells were maintained in RPMI 1640 medium with the addition of 10% ETS, 2 mm L-glutamine and 40 μg / ml gentamicin at 37 ° C. Studies have shown that the use of pre-irradiated saline (0.9% NaCl) for the antitumor drug doxorubicin significantly alters the conformational properties of its molecules. The minimum dose of high-energy electron irradiation (2 MeV) absorbed by the solvent, at which changes in the conformation states of the drugs dissolved in them are recorded, is equal to 4 kGy.
  • No Thumbnail Available
    Item
  • No Thumbnail Available
    Item
    ЕТИЧНІ АСПЕКТИ ФАРМАЦЕВТИЧНОЇ ПРАКТИКИ
    (ПВНЗ "Київський медичний університет", 2020-11-25) Білан О.А.; Брубейкер І.О.; Марченко-Толста К.С.; Новикова Л.Г.
  • No Thumbnail Available
    Item
    Antimonium crudum in pediatric skin conditions: A classical homeopathic case series
    (John Wiley & Sons, Inc, 2020-12-16) Mahesh Seema; Kozymenko Tamara; Kolomiiets Nataliia; Vithoulkas George
    Homeopathic Antimonium crudum may be useful in many pediatric skin conditions if prescribed on symptom similarity. It may especially be helpful in reducing the use of antibiotics and steroids in this age-group if proven to be effective through larger scientific studies
  • No Thumbnail Available
    Item
    NOVEL AGENTS FOR TREATMENT OF HERPES SIMPLEX VIRUS
    (Sole proprietorship -Gulyaeva V.М., 2021-03-04) Parchami Ghazaee Sepideh; Tumanov Viktor; Hamed Rezayatmand
  • No Thumbnail Available
    Item
    ANALYSIS OF THE APPLICATION OF ANTIBACTERIAL PREPARATIONS BY STUDENTS OF THE MEDICAL UNIVERSITY
    (Sole proprietorship -Gulyaeva V.М., 2021-03-27) Parchami Ghazaee Sepideh; Nikolaievska Yelyzaveta; Hryshkov Mykola; Tumanov Viktor
  • No Thumbnail Available
    Item
    ОСОБЛИВОСТІ АДАПТАЦІЇ ІНОЗЕМНИХ ЗДОБУВАЧІВ ОСВІТИ В ГАЛУЗІ ЗНАНЬ «ОХОРОНА ЗДОРОВ’Я» В УКРАЇНІ
    (Друкарня ФОП Гуляєва В.М., 2021-04-03) Марченко-Толста Катерина Сергіївна; Новикова Лариса Георгіївна; Ніколаєвська Єлизавета Олексіївна; Гришков Микола Миколайович
    Дане дослідження присвячено вивченню фізіологічної, психологічної та соціальної адаптації іноземних здобувачів освіти у вітчизняних закладах вищої освіти, а також методам полегшення та пришвидшення адаптації іноземців в українському соціокультурному середовищі для покращення професійної підготовки спеціалістів у галузі знань «Охорона здоров’я»
  • No Thumbnail Available
    Item
    ЕТИЧНІ АСПЕКТИ ФАРМАЦЕВТИЧНОЇ ПРАКТИКИ: ТОРГІВЛЯ, БІОЕТИКА, МАРКЕТИНГ
    (Національний фармацевтичний університет, 2021-04-15) Білан О.А.; Новикова Л.Г.; Марченко-Толста К.С.
    Питання фармацевтичної етики набувають особливого значення у сучасній фармацевтичній практиці для носіїв цінностей – фармацевтичних фахівців. Мета статті – огляд і упорядкування змін змісту і форм фармацевтичної практики, надання методичних рекомендацій для обґрунтування нових освітніх компонентів в освітньо-професійній програмі Фармація.
  • No Thumbnail Available
    Item
    ВИКОРИСТАННЯ ПРЕПАРАТУ ІЗ ОМЕЛИ ІСКАДОР В МЕДИЧНІЙ ПРАКТИЦІ
    (ФОП Клевцова Г.Є., 2021-04-16) Кіркілевська Л.М.; Кісіль О.В.; Маріловцева Н.О.
  • No Thumbnail Available
    Item
    METHODS TO MOTIVATE REMOTE TEACHERS IN A PANDEMIC ENVIRONMENT
    (RS Global Sp. z OO, 2021-04-17) Лозова Олена Василівна; Білан Ольга Анатоліївна; Новикова Лариса Георгіївна; Марченко-Толста Катерина Сергіївна
    The article examines the factors that affect the success of university remote teachers in a pandemic environment, the importance of maintaining the work motivation of teachers to ensure high performance e-learning, and the need for joint efforts by teachers and university administration to prevent professional burnout and maintain a sense of belonging to the team